|
D.V. Ergakov, A.G. Martov
Paradigm shift in combination therapy during the COVID-19 pandemic
|
№1 / 2021
|
|
Z.K. Gadzhieva, M.A. Gazimiev, Yu.B. Kazilov, V.A. Grigoryan
The combined symptoms of male lower urinary tract: current treatment options
|
№4 / 2018
|
|
A.G. Martov, D.V. Ergakov, A.B. Novikov
Current prospects for improving the quality of life of patients with internal stents
|
№2 / 2018
|
|
A.G. Martov, D.V. Ergakov, A.B. Novikov, N.G. Muzhetskaya, G.L. Esen'yan
Internal drainage in cancer patients: optimizing treatment of stent-related symptoms
|
№2 / 2016
|
|
Z.K. Gadzhieva, Yu.B. Kazilov
VValidation of the combined medical therapy for LUTS using α1-adrenergic blockers and M-cholinoblockers
|
№1 / 2016
|
|
A.A. Kamalov, E.S. Korshunova, G.R. Popov, L.A. Khodyreva, A.A.Dudareva, A.N. Nizov
Prospects for the treatment of idiopathic and neurogenic overactive bladder
|
№1 / 2015
|
|
M.V. Avksentyeva, K.V. Gerasimova, G.R. Khachatryan, M.Yu. Frolov, V.V. Omelyanovsky, N.A. Avksentyev
Pharmacoeconomic study of the use of drug solifenacin for the treatment of urge urinary incontinence in patients with overactive bladder syndrome
|
№5 / 2014
|
|
G.R. Kasyan
Flexible approach to the appointment of solifenacin: for whom and when?
|
№5 / 2013
|
|
Yu.G. Alyaev, Z.K. Gadzhieva, L.M. Rapoport, D.G. Tsarichenko, Yu.B. Kazilov
Imperative and obstructive urination disorders in patients with chronic inflammatory diseases of the urinary
|
№1 / 2013
|
|
Ibinayeva I.S., Apolikhina I.A., Makhmedzhanova F.N., Muslimova S.Z.
Solifenacin in the treatment of patients with overactive bladder: results of a randomized, double-blind, placebo-plans-controlled trial with increasing doses of the drug
|
№5 / 2012
|
Русский
